History
The USC Roski Eye Institute is widely recognized as a trailblazer in patient care, vision research and physician education. The U.S. News & World Report has ranked USC Ophthalmology among the top 10 ophthalmology programs in the country for 21 years. The institute is known for PROSE therapy (used to treat cornea disorders), advanced clinical trials, the latest surgical techniques and its partnership with Children's Hospital Los Angeles for pediatric and developmental eye care. * USC Roski Eye Institute is ranked in the top 10 for research funding by the National Eye Institute * USC Roski Eye Institute is ranked among the nation's top 10 Ophthalmology programs by both U.S. News & World Report * Mark Humayun, MD, PhD, led a team that developed the FDA-approved Argus II that restores some visual capabilities for certain blind patients. * Our Pediatric Ophthalmology Service is the only program in the nation with expertise in virtually every pediatric ophthalmologic subspecialty.
Specialties
The USC Roski Eye Institute at the University of Southern California is a local and national leader in eye care services. Recognized by U.S. News & World Report and Ophthalmology Times, the USC Roski Eye Institute has been ranked in the top 10 ophthalmology programs in the country for 21 years. * Complex Contact Lens and PROSE * Corneal and External Diseases * Glaucoma * Neuro-opthalmology, Orbital and Adult Strabismus * Ocular Oncology * Ocular Pathology * Oculofacial Plastic Surgery * Pediatric Ophthalmology * Cataract and Refractive Surgery * Uveitis and Ocular Inflammation * Vitreoretinal Surgery and Retinal Disease The USC Roski Eye Institute places our patients and their families at the center of care and surround them with the complete spectrum of diagnostic, treatment and preventive eye-care services. Improving the lives of people who experience vision loss is the focus of everything we do. Our physicians provide excellent care in the full spectrum of specialties and subspecialties to our patients, establishing relationships that inform and enhance research. Our quest to enhance vision and end blindness begins with understanding patient needs and developing new treatments that are needed most. We are known for PROSE therapy, FDA-approved Argus II Retinal Prosthesis System, clinical trials for severe uveitis, the latest surgical techniques for glaucoma, an international clinical study for neuro-ophthalmology, and our partnership with Children's Hospital Los Angeles.